Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

ented PFS data, further define satraplatin's clinical profile as a potential second-line treatment option in metastatic HRPC.

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival. Overall survival data are expected to be available later this year. Pharmion expects to complete the Marketing Authorization Application (MAA) for satraplatin for Europe in the second quarter of 2007. GPC Biotech recently completed the New Drug Application (NDA) submission for satraplatin to the U.S. Food and Drug Administration (FDA).

Safety findings were consistent with previous clinical studies involving satraplatin. The most common adverse reactions consisted of myelosuppression (bone marrow functions): Twenty-one percent of patients in the satraplatin arm experienced grade 3 or 4 thrombocytopenia; 14 percent had leucopenia and 21 percent had neutropenia. Eight percent of patients in the satraplatin arm experienced grade 3 or 4 gastrointestinal toxicities, including nausea (1.3%), vomiting (1.6%), diarrhea (2.1%) and constipation (2.1%). Five percent or less of patients in the satraplatin arm experienced grade 3 or 4 fatigue, grade 3 or 4 infections and pulmonary/respiratory grade 3 or 4 toxicities.

About Prostate Cancer

Prostate cancer is the most common cancer among men in the U.S. and Europe. Approximately 219,000 men in the U.S. are expected to be diagnosed with the disease in 2007 and over 27,000 men are expected to die from the disease. In the European Union, over 200,000 new cases are expected to be diagnosed, and over 60,000 patients are expected to die each year. Since the incidence of prostate cancer increases with age, the aging of the overall population is expected to further increase the number of prostate cancer patients.

Most patients diagnosed with prostate cancer initially receiv
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:10/1/2014)...  Varian Medical Systems (NYSE: VAR ) ... fourth quarter of fiscal year 2014 following the close ... news release will be followed by a teleconference available ... news release and a link to the conference call ... www.varian.com/investor .  To access the teleconference call and ...
(Date:10/1/2014)... , Oct. 1, 2014  Express Scripts (NASDAQ: ... nationally available 2015 Express Scripts Medicare ® Prescription ... network featuring Walgreens (NYSE: WAG ) (NASDAQ: ... value, choice and clinical support  for their Medicare dollars. ... Scripts Medicare Value or Choice ...
(Date:10/1/2014)... Mass. , Oct. 1, 2014   ... AEX: PHIA) today announced its eCareCoordinator and eCareCompanion ... U.S. Food and Drug Administration (FDA). A part ... telehealth programs , eCareCoordinator and eCareCompanion are focused ... the first clinical applications to be available through ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
(Date:10/1/2014)... 2014 Marriagelifeinsurance.com has released a ... for retired couples. , Senior citizens can purchase ... for their loved ones. A joint policy is cheaper, ... pass away. , Life insurance can be used ... can even be purchased online, as the application process ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater Toronto ... choice, is announcing a discounted cost on Botox units, ... “We’re doing this because we want to give as ... clinic in Toronto,” says Dr. Brian Sieber, founder of ... Aging Clinic, including laser facials, genesis laser facials, ...
(Date:10/1/2014)... October is national Breast Cancer Awareness ... plans while raising money for breast cancer research. Pelican ... Month in the effort to find a cure. ... importance of having access to clean, healthy water. Research ... to certain forms of cancer. , The Problem ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... , Statement attributable to: J. James Rohack, M.D. President, ... that Medical Liability Reform is Needed , , ... is unacceptable. The AMA will continue to work for reform that makes ... opportunity this year to achieve meaningful health reform for America,s patients and ...
... WASHINGTON, Sept. 9 Change to Win chair Anna ... Congress on health care reform. , , ... care system that has become a tremendous burden on working families ... act now by implementing comprehensive health care reform that guarantees all ...
... Sept. 9 In commemoration of the first September 11 National ... Los Angeles will host three 2-hour volunteer orientations for 100+ youth and ... tour of the chapter,s new state of the art Emergency Operation Center, ... recent California wildfires. , , What: ...
... , WASHINGTON, Sept. 9 Speaker Nancy Pelosi ... session of Congress on the urgent need for health insurance reform: ... a forceful case to the Congress and the country for long-overdue ... to real progress on this issue that touches the lives of ...
... MECHANICSBURG, Pa., Sept. 9 Select Medical Holdings Corporation ("Select"), ... of its initial public offering of 33,333,333 shares of Select ... to be between $11.00 and $13.00 ... shares by Select, and Goldman, Sachs & Co., Morgan Stanley ...
... , , , INDIANAPOLIS, ... announced today it will begin marketing its 2010 Medicare Advantage and 2010 ... begin enrolling beneficiaries in its Medicare Advantage and Medicare Part D health ... , , The Centers for Medicare and Medicaid Services ...
Cached Medicine News:Health News:AMA Reaction to President Obama's Address on Health-System Reform 2Health News:Red Cross Participates in September 11th National Day of Service and Remembrance 2Health News:Pelosi on President Obama's Health Reform Speech: 'The Time to Act Is Now; And We Will' 2Health News:Select Medical Holdings Corporation Commences Initial Public Offering of Common Stock 2Health News:Statement on WellPoint's Re-Entry into Medicare Market 2
0.2 mm, 90o angled tip. Flat smooth handle with polished finish....
Nucleus manipulator facilitates lens rotation during phacoemulsification....
Straight shaft with 0.2 mm hour glass shape tip. Round knurled handle with dull finish. Manufactured in titanium....
Ideal for nucleus manipulation during phacoemulsification. Also used for manipulating and rotating IOLs within the anterior chamber. Round knurled handle...
Medicine Products: